Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
Bullboard Posts
User Avatar Image
(4)
•••
Post by eyeNteeon Jan 21, 2014 10:19pm
192 Views
Post# 22118586

Canadian Biotech comes back to life

Canadian Biotech comes back to lifeVentripoint mentioned in top story by Tony Pullen D&D securities                                                         v

Among the newer crop of companies I would cite Medifocus (TSX:V.MFS, Stock Forum), Delmar Pharma (OBB:DMPI, Stock Forum), Sernova (TSX:V.SVA, Stock Forum) and VentriPoint (TSX:V.VPT, Stock Forum) as companies with new strategies or technologies with game-changing potential in their respective fields. Some or all of them will be certain to achieve a following if the renewed interest in the space finds them. Medifocus has recently reacquired its management team’s original invention from Boston Scientific and is in the process of reestablishing that product’s $30-million revenue potential. This brings a welcome revenue stream to its multi-faceted oncology platform.

Delmar is repurposing a therapeutic agent from the 1990s as a potential treatment for glioblastoma, one of cancer’s worst, most aggressive forms. Sernova is developing a new, cutting-edge approach to diabetes management. VentriPoint has a major, cost effective, cloud-based software solution for heart diagnosis that is currently in front of the FDA. Approval would bring a major value inflection.

Read more at https://www.stockhouse.com/opinion/independent-reports/2014/01/21/is-canadian-biotech-coming-to-life#xIWgJyFzyhVd9o47.99
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities